Cargando…
Modified R-CODOX-M/IVAC chemotherapy regimens in Chinese patients with untreated sporadic Burkitt lymphoma
OBJECTIVE: To characterize modified R-CODOX-M/IVAC-based chemotherapy to lower the severe adverse events in Chinese adult patients with sporadic Burkitt lymphoma. METHODS: We enrolled a retrospective cohort including 123 adult patients with untreated sporadic Burkitt lymphoma from August 2008 to Sep...
Autores principales: | Chen, Meiting, Wang, Zhao, Fang, Xiaojie, Yao, Yuyi, Ren, Quanguang, Chen, Zegeng, Tian, Ying, Pan, Fei, Li, Xiaoqian, Li, Zhiming, Cai, Qingqing, Huang, He, Lin, Tongyu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Compuscript
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330526/ https://www.ncbi.nlm.nih.gov/pubmed/35979854 http://dx.doi.org/10.20892/j.issn.2095-3941.2020.0314 |
Ejemplares similares
-
HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era
por: Rodrigo, J. A., et al.
Publicado: (2012) -
Treatment of grey zone lymphoma using the R-CODOX-M/R-IVAC protocol: Two case reports
por: Yang, Xiao-Yan, et al.
Publicado: (2017) -
A Case of Double Expresser Diffuse Large B Cell Lymphoma Treated with R-CODOX-M/R-IVAC
por: Bemis, Thomas, et al.
Publicado: (2019) -
Favourable outcomes for high‐risk Burkitt lymphoma patients (IPI 3‐5) treated with rituximab plus CODOX‐M/IVAC: Results of a phase 2 UK NCRI trial
por: Phillips, Elizabeth H., et al.
Publicado: (2020) -
Modified dose intensive R- CODOX-M/IVAC for HIV-associated burkitt (BL) (AMC 048) shows efficacy and tolerability, and predictive potential of IRF4/MUM1 expression
por: Noy, Ariela, et al.
Publicado: (2012)